SER Serina Therapeutics Inc.

Price (delayed)

$1.92

Market cap

$28.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

$7.44M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 14

agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic ...

Highlights
Serina Therapeutics's gross profit has surged by 155% YoY
The revenue has surged by 155% year-on-year
The net income has declined by 11% since the previous quarter
The company's EPS fell by 4.7% QoQ

Key stats

What are the main financial stats of SER

SER stock price

How has the Serina Therapeutics stock price performed over time
Intraday
7.26%
1 week
-1.54%
1 month
1.05%
1 year
-67.57%
YTD
0.37%
QTD
-1.03%

Financial performance

How have Serina Therapeutics's revenue and profit performed over time
Revenue
$130,000
Gross profit
$130,000
Operating income
-$24.44M
Net income
-$21.27M
Gross margin
100%
Net margin
-16,359.2%
Serina Therapeutics's gross profit has surged by 155% YoY
The revenue has surged by 155% year-on-year
The company's operating margin has surged by 53% YoY
The company's operating income fell by 19% YoY

Price vs fundamentals

How does SER's price correlate with its fundamentals

Growth

What is Serina Therapeutics's growth rate over time

Valuation

What is Serina Therapeutics stock price valuation
P/E
N/A
P/B
1.34
P/S
177.92
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57.22
The company's EPS fell by 4.7% QoQ
The revenue has surged by 155% year-on-year
The price to sales (P/S) is 48% lower than the last 4 quarters average of 320.4 and 35% lower than the 5-year quarterly average of 255.5

Efficiency

How efficient is Serina Therapeutics business performance
The ROIC has shrunk by 137% QoQ
Serina Therapeutics's ROE has soared by 73% from the previous quarter
Serina Therapeutics's ROA has increased by 30% from the previous quarter
The company's return on sales fell by 10% QoQ

Dividends

What is SER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SER.

Financial health

How did Serina Therapeutics financials performed over time
Serina Therapeutics's total assets is 182% higher than its total liabilities
The company's current ratio has surged by 144% QoQ and by 71% YoY
The quick ratio has surged by 114% year-on-year
The company's debt is 82% lower than its equity
The debt to equity has surged by 100% since the previous quarter and by 38% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.